Modulation of cell fates and activities by phthalazinediones

Details for Australian Patent Application No. 2005335199 (hide)

Owner Bach Pharma, Inc.

Inventors Henry, Mark O.; Lynn, William S.

Agent Shelston IP

Pub. Number AU-A-2005335199

PCT Pub. Number WO2007/018546

Priority 11/199,394 08.08.05 US

Filing date 17 August 2005

Wipo publication date 15 February 2007

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 31/19 (2006.01)

A61K 31/195 (2006.01)

A61K 31/385 (2006.01) - having two or more sulfur atoms in the same ring

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

Event Publications

28 February 2008 PCT application entered the National Phase

  PCT publication WO2007/018546 Priority application(s): WO2007/018546

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005335203-Compositions and methods for the detection of HIV-1/HIV-2 infection

2005335197-Tri-block copolymers for nanospherebased drug delivery